{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"36.2","upperLimit":"56.2","value":"46.1"},{"groupId":"OG001","lowerLimit":"41.3","upperLimit":"70.0","value":"56.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"102"},{"groupId":"OG001","value":"50"}],"units":"Participants"}],"description":"Confirmed objective response rate (ORR), defined as the percentage of participants with complete response (CR) or partial response (PR), will be assessed by the Investigator based on Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1. CR was defined as a disappearance of all target lesions and PR was defined as at least a 30% decrease in the sum of diameters of target lesions.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants randomized to receive trastuzumab deruxtecan 5.4 mg/kg, administered by intravenous infusion every 3 weeks (Q3W).","id":"OG000","title":"Trastuzumab Deruxtecan 5.4 mg/kg"},{"description":"Participants randomized to receive trastuzumab deruxtecan 6.4 mg/kg, administered by intravenous infusion every 3 weeks (Q3W).","id":"OG001","title":"Trastuzumab Deruxtecan 6.4 mg/kg"}],"paramType":"NUMBER","populationDescription":"Full Analysis Set includes all subjects for whom study treatment was assigned by randomization","reportingStatus":"POSTED","timeFrame":"9 months after the last participant is randomized or later to data cut off, up to approximately 35 months","title":"Percentage of Participants With Confirmed Objective Response Rate by Investigator Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung CancerTumors","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}